Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE study (NCT03793166) exploring immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) followed by nivolumab or nivolumab with cabozantinib (Cabometyx) for patients with intermediate/poor-risk metastatic clear cell renal cell carcinoma
Zhang, who is an associate professor at UT Southwestern Medical Center, was interviewed during the 2021 Kidney cancer research summit in Philadelphia, Pennsylvania.
Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists
March 31st 2021“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.